טוען...
Dexmedetomidine ameliorates high‐fat diet‐induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice
Fatty liver disease is one of the main hepatic complications associated with obesity. To date, there are no therapeutic drugs approved for this pathology. Insulin resistance (IR) is implicated both in pathogenesis of nonalcoholic fatty liver disease (NAFLD) and in disease progression from steatosis...
שמור ב:
| הוצא לאור ב: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7753983/ https://ncbi.nlm.nih.gov/pubmed/33474802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.700 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|